stockportfolio.pro
EW vs MDLN: Which Stock Is the Better Buy?
Edwards Lifesciences Corporation and Medline Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — EW vs MDLN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Edwards Lifesciences Corporation (EW) | Medline Inc. (MDLN) | |
|---|---|---|
| Market cap | $54.3B | $64.5B |
| Revenue (latest FY) | $6.07B | $28.43B |
| Net income (latest FY) | $1.07B | $1.16B |
| Revenue growth (5y CAGR) | 6.7% | 7.0% |
| Net margin | 17.7% | 4.1% |
| Return on equity | 10.4% | 10.8% |
| P/E ratio | 51.0 | 31.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 4 |
| Positive free cash flow | Yes | Yes |
See the full EW vs MDLN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open EW's full financials → Open MDLN's full financials →Frequently asked questions
Which is bigger, EW or MDLN?
Medline Inc. is larger by market capitalization — $64.5B versus $54.3B.
Which grows faster, EW or MDLN?
Over the last five fiscal years, Medline Inc. grew revenue faster — 7.0%/yr versus 6.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.